Nasu K, Nakarai I, Horiuchi M, Shinoda A
Dept. of Surgery, National Sanatorium Omuta Hospital.
Gan To Kagaku Ryoho. 1988 Aug;15(8 Pt 2):2410-3.
In 8 cases of advanced and/or relapsed gastric cancer (7 cases advanced, 1 case relapsed), we undertook combination chemotherapy with systemic administration of cisplatin and celiac arterial infusion of carboquone intermittently under continuous administration of OK-432 i.m. and UFT p.o. The male to female ratio was 5 to 3 and the age distribution from 53 to 77 years (mean age, 70 years.) Eight cases were divided into the following histological types: 1 papillary adenocarcinoma, 1 well-differentiated tubular adenocarcinoma, 3 moderately differentiated tubular adenocarcinomas, and 3 poorly differentiated adenocarcinomas. Complete response (CR) was obtained in one case, partial response (PR) in four cases, minor response (MR) in two cases, and no change (NC) in one case. The response rate was 62.5%. CR was noted in a relapsed case. The median survival time from the beginning of the chemotherapy was 8 months (ranging from 6 to 13 months). The major toxicity was bone marrow suppression, but there were no cases of serious renal damage.
在8例晚期和/或复发性胃癌患者中（7例为晚期，1例为复发性），我们采用了联合化疗，即静脉注射顺铂并间断经腹腔动脉灌注卡波醌，同时持续肌肉注射OK - 432和口服优福定。男女比例为5比3，年龄分布在53岁至77岁之间（平均年龄70岁）。8例患者分为以下组织学类型：1例乳头状腺癌，1例高分化管状腺癌，3例中分化管状腺癌，3例低分化腺癌。1例获得完全缓解（CR），4例部分缓解（PR），2例轻度缓解（MR），1例无变化（NC）。缓解率为62.5%。1例复发性病例出现完全缓解。化疗开始后的中位生存时间为8个月（6至13个月）。主要毒性为骨髓抑制，但无严重肾损伤病例。
